Literature DB >> 29395795

Comparison of Interobserver Agreement and Diagnostic Accuracy for IASLC/ITMIG Thymic Epithelial Tumor Staging Among Co-registered FDG-PET/MRI, Whole-body MRI, Integrated FDG-PET/CT, and Conventional Imaging Examination with and without Contrast Media Administrations.

Yoshiharu Ohno1, Yuji Kishida2, Shinichiro Seki3, Hisanobu Koyama2, Masao Yui4, Kota Aoyagi4, Takeshi Yoshikawa3.   

Abstract

RATIONALE AND
OBJECTIVES: The purpose of this study was to compare the interobserver agreements and diagnostic accuracies for IASLC/ITMIG (International Association for the Study of Lung Cancer/International Thymic Malignancies Interest Group) thymic epithelial tumor staging of co-registered fluorodeoxyglucose positron emission tomography/magnetic resonance imaging (FDG-PET/MRI), MRI, integrated fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT), and conventional imaging examination.
MATERIALS AND METHODS: Prospective whole-body MRI including diffusion-weighted imaging, integrated PET/CTs, conventional imaging examinations, pathological examinations, and surgical reports, as well as follow-up examinations, were performed for 64 consecutive patients with thymic epithelial tumor. All FDG-PET/MRIs were co-registered PET data with MRI. TNM staging was evaluated by two radiologists on the basis of the IASLC/ITMIG thymic epithelial tumor staging system. Kappa statistics were determined for evaluations of agreements of all factors between each of the methods and final diagnosis. Finally, the diagnostic accuracy of each factor and of determination of the clinical stage was statistically compared to each other using McNemar test.
RESULTS: Agreements for all factors between each method and final diagnosis were assessed as fair, moderate, substantial, or almost perfect (0.28 ≤ kappa value ≤ 0.80; P < .0001). Diagnostic accuracy for N factor of PET/MRI (93.8% [60/64]) and MRI (93.8% [60/64]) was significantly higher than that of conventional imaging examination (81.3% [52/64] vs PET/MRI and MRI; P = .008). In addition, diagnostic accuracy for staging of PET/MRI (84.4% [54/64]) and MRI (84.4 [54/64]) was significantly higher than that of conventional imaging examination (71.9% [46/64] vs PET/MRI and MRI; P = .008).
CONCLUSIONS: Whole-body PET/MRI, MRI, and PET/CT have better interobserver agreements and accuracies than conventional imaging examination for the new IASLC/ITMIG thymic epithelial tumor staging.
Copyright © 2017 The Association of University Radiologists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Magnetic resonance imaging; mediastinum; positron emission tomography and computed tomography; thymoma; thymus

Mesh:

Substances:

Year:  2018        PMID: 29395795     DOI: 10.1016/j.acra.2017.12.016

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  4 in total

1.  Prognostic Significance of Metabolic Parameters by 18F-FDG PET/CT in Thymic Epithelial Tumors.

Authors:  Joohee Lee; Young Seok Cho; Jhingook Kim; Young Mog Shim; Kyung-Han Lee; Joon Young Choi
Journal:  Cancers (Basel)       Date:  2021-02-09       Impact factor: 6.639

Review 2.  State-of-the-art MR Imaging for Thoracic Diseases.

Authors:  Yumi Tanaka; Yoshiharu Ohno; Satomu Hanamatsu; Yuki Obama; Takahiro Ueda; Hirotaka Ikeda; Akiyoshi Iwase; Takashi Fukuba; Hidekazu Hattori; Kazuhiro Murayama; Takeshi Yoshikawa; Daisuke Takenaka; Hisanobu Koyama; Hiroshi Toyama
Journal:  Magn Reson Med Sci       Date:  2021-04-29       Impact factor: 2.760

3.  Usefulness of 18F-FDG PET/CT in treatment-naive patients with thymic squamous cell carcinoma.

Authors:  Yuan Li; Yi Li; Yan Huang; Xiaodong Wu; Zi Yang; Chunyan Wu; Lei Jiang
Journal:  Ann Nucl Med       Date:  2021-06-08       Impact factor: 2.668

Review 4.  Determining extent of invasion and follow-up of thymic epithelial malignancies.

Authors:  Marcelo F Benveniste; Sonia L Betancourt Cuellar; Brett W Carter; Girish S Shroff; Carol Wu; Edith M Marom
Journal:  Mediastinum       Date:  2019-07-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.